To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Sulforaphane reduces hepa… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Journal article
Authors A. S. Axelsson
E. Tubbs
B. Mecham
S. Chacko
H. A. Nenonen
Y. Z. Tang
J. W. Fahey
J. M. J. Derry
C. B. Wollheim
N. Wierup
M. W. Haymond
S. H. Friend
H. Mulder
Anders H. Rosengren
Published in Science Translational Medicine
Volume 9
Issue 394
ISSN 1946-6234
Publication year 2017
Published at Institute of Neuroscience and Physiology
Language en
Links stm.sciencemag.org/content/9/394/ea...
Keywords gene-expression, insulin-resistance, induced inhibition, broccoli, sprouts, oxidative stress, network analysis, fatty liver, in-vivo, nrf2, disease, Cell Biology, Research & Experimental Medicine, hwarze pe, 1985, carcinogenesis, v6, p777, fronzo ra, 1989, metabolism-clinical and experimental, v38, p387
Subject categories Clinical Medicine

Abstract

A potentially useful approach for drug discovery is to connect gene expression profiles of disease-affected tissues ("disease signatures") to drug signatures, but it remains to be shown whether it can be used to identify clinically relevant treatment options. We analyzed coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue. By interrogating a library of 3800 drug signatures, we identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin. Finally, sulforaphane, provided as concentrated broccoli sprout extract, reduced fasting blood glucose and glycated hemoglobin (HbA1c) in obese patients with dysregulated type 2 diabetes.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?